SCHEMBL20914149

SCHEMBL20914149

COc1cccc2oc(-c3c(C(=O)N4CCCCC4)[nH]c4c(-c5ccccc5)c(C(F)(F)F)nn4c3=O)nc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 3/20 0.35
▸ ACACB O00763 1/20 0.35
▸ HPGD P15428 6/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ MGLL Q99685 1/20 0.34
▸ CTSA P10619 1/20 0.34
▸ ALDH1A1 P00352 4/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ NPC1 O15118 3/20 0.33
▸ RAB9A P51151 3/20 0.33
▸ TSHR P16473 1/20 0.33
▸ ITGB1 P05556 1/20 0.33
▸ ITGA4 P13612 1/20 0.33
▸ POLB P06746 2/20 0.33
▸ ADORA2A P29274 2/20 0.33
▸ ADORA2B P29275 1/20 0.33
▸ ADORA1 P30542 1/20 0.33
▸ SCN9A Q15858 1/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20819040 0.89 TNKS (0.35) KDM4EALDH1A1HSD17B10TSHRPOLB
SCHEMBL20913994 0.89 POLB (0.37) KDM4EMAPTALDH1A1HSD17B10TSHR
SCHEMBL20914091 0.88 TNKS (0.34) KDM4EMAPTALDH1A1HSD17B10TSHR
SCHEMBL20914227 0.86 ROCK2 (0.37) —
SCHEMBL20914230 0.86 ROCK2 (0.37) —
SCHEMBL20819031 0.86 ARF6 (0.37) KDM4EMAPTALDH1A1HSD17B10TSHR
SCHEMBL20819079 0.85 TNKS (0.38) HPGDKDM4EMAPTALDH1A1HSD17B10
SCHEMBL20914203 0.84 TNKS (0.37) HPGDKDM4EMAPTALDH1A1HSD17B10
SCHEMBL20914000 0.84 F2RL3 (0.33) PDE4BHSD17B10TSHRADORA2AMEN1
SCHEMBL20819069 0.84 TNKS (0.37) HPGDKDM4EMAPTALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 PDE4B 190/4885ACACB 2054/4885HPGD 280/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 PDE4B 190/4885ACACB 2054/4885HPGD 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback